Pharming Group (NASDAQ:PHAR) Sees Significant Drop in Short Interest

Pharming Group (NASDAQ:PHAR - Get Free Report) was the recipient of a significant decrease in short interest in May. As of May 15th, there was short interest totalling 1,300 shares, a decrease of 18.8% from the April 30th total of 1,600 shares. Based on an average trading volume of 5,100 shares, the days-to-cover ratio is presently 0.3 days. Approximately 0.0% of the shares of the company are sold short.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Oppenheimer upped their price target on shares of Pharming Group from $30.00 to $39.00 and gave the stock an "outperform" rating in a research report on Friday, March 14th. HC Wainwright reiterated a "buy" rating and issued a $37.00 price objective on shares of Pharming Group in a report on Thursday, March 20th.

Pharming Group Stock Performance

Shares of NASDAQ:PHAR traded up $0.73 on Friday, hitting $11.94. The company had a trading volume of 2,119 shares, compared to its average volume of 6,249. Pharming Group has a 1-year low of $6.65 and a 1-year high of $12.61. The stock has a market cap of $812.36 million, a price-to-earnings ratio of -45.93 and a beta of 0.02. The stock has a 50 day moving average price of $9.27 and a 200 day moving average price of $9.02. The company has a current ratio of 3.53, a quick ratio of 2.76 and a debt-to-equity ratio of 0.41.

Pharming Group (NASDAQ:PHAR - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.03. Pharming Group had a negative net margin of 6.09% and a negative return on equity of 7.65%. The firm had revenue of $79.09 million for the quarter, compared to the consensus estimate of $67.74 million. Analysts expect that Pharming Group will post -0.2 EPS for the current year.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.